Cargando…

Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020

OBJECTIVES: A nationwide cross-sectional epidemiological survey was conducted to capture the true extent of coronavirus disease 2019 (COVID-19) exposure in Senegal. METHODS: Multi-stage random cluster sampling of households was performed between October and November 2020, at the end of the first wav...

Descripción completa

Detalles Bibliográficos
Autores principales: Talla, Cheikh, Loucoubar, Cheikh, Roka, Jerlie Loko, Barry, Mamadou A., Ndiaye, Seynabou, Diarra, Maryam, Thiam, Mareme Seye, Faye, Oumar, Dia, Moussa, Diop, Mamadou, Ndiaye, Oumar, Tall, Adama, Faye, Rokhaya, Mbow, Adji Astou, Diouf, Babacar, Diallo, Jean Pierre, Keita, Ibrahima Mamby, Ndiaye, Mamadou, Woudenberg, Tom, White, Michael, Ting, Jim, Diagne, Cheikh Tidiane, Pasi, Omer, Diop, Boly, Sall, Amadou A., Vigan-Womas, Inès, Faye, Ousmane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/
https://www.ncbi.nlm.nih.gov/pubmed/35720135
http://dx.doi.org/10.1016/j.ijregi.2022.02.007
_version_ 1784663513471385600
author Talla, Cheikh
Loucoubar, Cheikh
Roka, Jerlie Loko
Barry, Mamadou A.
Ndiaye, Seynabou
Diarra, Maryam
Thiam, Mareme Seye
Faye, Oumar
Dia, Moussa
Diop, Mamadou
Ndiaye, Oumar
Tall, Adama
Faye, Rokhaya
Mbow, Adji Astou
Diouf, Babacar
Diallo, Jean Pierre
Keita, Ibrahima Mamby
Ndiaye, Mamadou
Woudenberg, Tom
White, Michael
Ting, Jim
Diagne, Cheikh Tidiane
Pasi, Omer
Diop, Boly
Sall, Amadou A.
Vigan-Womas, Inès
Faye, Ousmane
author_facet Talla, Cheikh
Loucoubar, Cheikh
Roka, Jerlie Loko
Barry, Mamadou A.
Ndiaye, Seynabou
Diarra, Maryam
Thiam, Mareme Seye
Faye, Oumar
Dia, Moussa
Diop, Mamadou
Ndiaye, Oumar
Tall, Adama
Faye, Rokhaya
Mbow, Adji Astou
Diouf, Babacar
Diallo, Jean Pierre
Keita, Ibrahima Mamby
Ndiaye, Mamadou
Woudenberg, Tom
White, Michael
Ting, Jim
Diagne, Cheikh Tidiane
Pasi, Omer
Diop, Boly
Sall, Amadou A.
Vigan-Womas, Inès
Faye, Ousmane
author_sort Talla, Cheikh
collection PubMed
description OBJECTIVES: A nationwide cross-sectional epidemiological survey was conducted to capture the true extent of coronavirus disease 2019 (COVID-19) exposure in Senegal. METHODS: Multi-stage random cluster sampling of households was performed between October and November 2020, at the end of the first wave of COVID-19 transmission. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were screened using three distinct ELISA assays. Adjusted prevalence rates for the survey design were calculated for each test separately, and thereafter combined. Crude and adjusted prevalence rates based on test performance were estimated to assess the seroprevalence. As some samples were collected in high malaria endemic areas, the relationship between SARS-CoV-2 seroreactivity and antimalarial humoral immunity was also investigated. RESULTS: Of the 1463 participants included in this study, 58.8% were female and 41.2% were male; their mean age was 29.2 years (range 0.20–84.8.0 years). The national seroprevalence was estimated at 28.4% (95% confidence interval 26.1–30.8%). There was substantial regional variability. All age groups were impacted, and the prevalence of SARS-CoV-2 was comparable in the symptomatic and asymptomatic groups. An estimated 4 744 392 (95% confidence interval 4 360 164–5 145 327) were potentially infected with SARS-CoV-2 in Senegal, while 16 089 COVID-19 RT-PCR laboratory-confirmed cases were reported by the national surveillance. No correlation was found between SARS-CoV-2 and Plasmodium seroreactivity. CONCLUSIONS: These results provide a better estimate of SARS-CoV-2 dissemination in the Senegalese population. Preventive and control measures need to be reinforced in the country and especially in the south border regions.
format Online
Article
Text
id pubmed-8897837
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88978372022-03-07 Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020 Talla, Cheikh Loucoubar, Cheikh Roka, Jerlie Loko Barry, Mamadou A. Ndiaye, Seynabou Diarra, Maryam Thiam, Mareme Seye Faye, Oumar Dia, Moussa Diop, Mamadou Ndiaye, Oumar Tall, Adama Faye, Rokhaya Mbow, Adji Astou Diouf, Babacar Diallo, Jean Pierre Keita, Ibrahima Mamby Ndiaye, Mamadou Woudenberg, Tom White, Michael Ting, Jim Diagne, Cheikh Tidiane Pasi, Omer Diop, Boly Sall, Amadou A. Vigan-Womas, Inès Faye, Ousmane IJID Reg Coronavirus (COVID-19) Collection OBJECTIVES: A nationwide cross-sectional epidemiological survey was conducted to capture the true extent of coronavirus disease 2019 (COVID-19) exposure in Senegal. METHODS: Multi-stage random cluster sampling of households was performed between October and November 2020, at the end of the first wave of COVID-19 transmission. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were screened using three distinct ELISA assays. Adjusted prevalence rates for the survey design were calculated for each test separately, and thereafter combined. Crude and adjusted prevalence rates based on test performance were estimated to assess the seroprevalence. As some samples were collected in high malaria endemic areas, the relationship between SARS-CoV-2 seroreactivity and antimalarial humoral immunity was also investigated. RESULTS: Of the 1463 participants included in this study, 58.8% were female and 41.2% were male; their mean age was 29.2 years (range 0.20–84.8.0 years). The national seroprevalence was estimated at 28.4% (95% confidence interval 26.1–30.8%). There was substantial regional variability. All age groups were impacted, and the prevalence of SARS-CoV-2 was comparable in the symptomatic and asymptomatic groups. An estimated 4 744 392 (95% confidence interval 4 360 164–5 145 327) were potentially infected with SARS-CoV-2 in Senegal, while 16 089 COVID-19 RT-PCR laboratory-confirmed cases were reported by the national surveillance. No correlation was found between SARS-CoV-2 and Plasmodium seroreactivity. CONCLUSIONS: These results provide a better estimate of SARS-CoV-2 dissemination in the Senegalese population. Preventive and control measures need to be reinforced in the country and especially in the south border regions. Elsevier 2022-03-05 /pmc/articles/PMC8897837/ /pubmed/35720135 http://dx.doi.org/10.1016/j.ijregi.2022.02.007 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Coronavirus (COVID-19) Collection
Talla, Cheikh
Loucoubar, Cheikh
Roka, Jerlie Loko
Barry, Mamadou A.
Ndiaye, Seynabou
Diarra, Maryam
Thiam, Mareme Seye
Faye, Oumar
Dia, Moussa
Diop, Mamadou
Ndiaye, Oumar
Tall, Adama
Faye, Rokhaya
Mbow, Adji Astou
Diouf, Babacar
Diallo, Jean Pierre
Keita, Ibrahima Mamby
Ndiaye, Mamadou
Woudenberg, Tom
White, Michael
Ting, Jim
Diagne, Cheikh Tidiane
Pasi, Omer
Diop, Boly
Sall, Amadou A.
Vigan-Womas, Inès
Faye, Ousmane
Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020
title Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020
title_full Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020
title_fullStr Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020
title_full_unstemmed Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020
title_short Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020
title_sort seroprevalence of anti-sars-cov-2 antibodies in senegal: a national population-based cross-sectional survey, between october and november 2020
topic Coronavirus (COVID-19) Collection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897837/
https://www.ncbi.nlm.nih.gov/pubmed/35720135
http://dx.doi.org/10.1016/j.ijregi.2022.02.007
work_keys_str_mv AT tallacheikh seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT loucoubarcheikh seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT rokajerlieloko seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT barrymamadoua seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT ndiayeseynabou seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT diarramaryam seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT thiammaremeseye seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT fayeoumar seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT diamoussa seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT diopmamadou seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT ndiayeoumar seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT talladama seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT fayerokhaya seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT mbowadjiastou seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT dioufbabacar seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT diallojeanpierre seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT keitaibrahimamamby seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT ndiayemamadou seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT woudenbergtom seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT whitemichael seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT tingjim seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT diagnecheikhtidiane seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT pasiomer seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT diopboly seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT sallamadoua seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT viganwomasines seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020
AT fayeousmane seroprevalenceofantisarscov2antibodiesinsenegalanationalpopulationbasedcrosssectionalsurveybetweenoctoberandnovember2020